Zobrazeno 1 - 10
of 526
pro vyhledávání: '"R. Buelow"'
Autor:
Daelynn R. Buelow, Jason T. Anderson, Stanley B. Pounds, Lei Shi, Jatinder K. Lamba, Shuiying Hu, Alice A. Gibson, Emily A. Goodwin, Alex Sparreboom, Sharyn D. Baker
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 1, Pp 137-142 (2021)
Reduced expression of the uptake transporter, OCTN1 (SLC22A4), has been reported as a strong predictor of poor event‐free and overall survival in multiple cohorts of patients with acute myeloid leukemia (AML) receiving the cytidine nucleoside analo
Externí odkaz:
https://doaj.org/article/60a03cb38eac4e618ecd1c78891d4e02
Autor:
Daelynn R. Buelow, Stanley B. Pounds, Yong‐Dong Wang, Lei Shi, Yongjin Li, David Finkelstein, Sheila Shurtleff, Geoffrey Neale, Hiroto Inaba, Raul C. Ribeiro, Reid Palumbo, Dominique Garrison, Shelley J. Orwick, James S. Blachly, Karl Kroll, John C. Byrd, Tanja A. Gruber, Jeffrey E. Rubnitz, Sharyn D. Baker
Publikováno v:
Clinical and Translational Science, Vol 12, Iss 6, Pp 641-647 (2019)
Fms‐like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations, common in pediatric acute myeloid leukemia (AML), associate with early relapse and poor prognosis. Past studies have suggested additional cooperative mutations are requi
Externí odkaz:
https://doaj.org/article/b729c098fb6e48d4859209165db95c5f
Autor:
Christina D. Drenberg, Anang Shelat, Jinjun Dang, Anitria Cotton, Shelley J. Orwick, Mengyu Li, Jae Yoon Jeon, Qiang Fu, Daelynn R. Buelow, Marissa Pioso, Shuiying Hu, Hiroto Inaba, Raul C. Ribeiro, Jeffrey E. Rubnitz, Tanja A. Gruber, R. Kiplin Guy, Sharyn D. Baker
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-16 (2019)
Pediatric AML is traditionally treated with chemotherapy and stem cell transplant but some subsets of patients have a poor response to therapy. Here, the authors perform a high throughput screen and identify several FDA approved drugs that might be u
Externí odkaz:
https://doaj.org/article/f909cbdab341455d9f702b6081a46e6f
Autor:
Haijiao Zhang, Samantha Savage, Anna Reister Schultz, Daniel Bottomly, Libbey White, Erik Segerdell, Beth Wilmot, Shannon K. McWeeney, Christopher A. Eide, Tamilla Nechiporuk, Amy Carlos, Rachel Henson, Chenwei Lin, Robert Searles, Hoang Ho, Yee Ling Lam, Richard Sweat, Courtney Follit, Vinay Jain, Evan Lind, Gautam Borthakur, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Jorge Cortes, Robert Collins, Daelynn R. Buelow, Sharyn D. Baker, Brian J. Druker, Jeffrey W. Tyner
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
FLT3 is commonly mutated in acute myeloid leukaemia and treatment with FLT3 inhibitors often ends with relapse. Here, the authors perform exome sequencing of samples from patients treated with the FLT3 inhibitor, crenolanib, to show that resistance o
Externí odkaz:
https://doaj.org/article/998f439604e74cef95464ecda676fa5a
Autor:
Jae Yoon Jeon, Daelynn R. Buelow, Dominique A. Garrison, Mingshan Niu, Eric D. Eisenmann, Kevin M. Huang, Megan E. Zavorka Thomas, Robert H. Weber, Clifford J. Whatcott, Steve L. Warner, Shelley J. Orwick, Bridget Carmichael, Emily Stahl, Lindsey T. Brinton, Rosa Lapalombella, James S. Blachly, Erin Hertlein, John C. Byrd, Bhavana Bhatnagar, Sharyn D. Baker
Publikováno v:
JCI Insight, Vol 5, Iss 23 (2020)
Effective treatment for AML is challenging due to the presence of clonal heterogeneity and the evolution of polyclonal drug resistance. Here, we report that TP-0903 has potent activity against protein kinases related to STAT, AKT, and ERK signaling,
Externí odkaz:
https://doaj.org/article/4bacc087740b4a43a3e2e850f46e9e4b
Publikováno v:
Nurse Educator. 48:E79-E84
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d171bdadbc15bb7199af38a955dacbaf
https://doi.org/10.1097/nne.0000000000001340
https://doi.org/10.1097/nne.0000000000001340
Publikováno v:
Online Learning, Vol 22, Iss 4 (2019)
University students are increasingly demanding that traditionally taught courses are converted to an online platform. While quality standards are in place for the format and organization of online courses, professors often are left wondering what act
Externí odkaz:
https://doaj.org/article/bd5a61d4fa2e4ab4b877f5482f7d3903
Autor:
Jack C. Stromatt, Daelynn R. Buelow, Shelly J. Orwick, Eric Eisenmann, Navjot S. Pabla, Bradly W. Blaser, Sharyn D. Baker
Publikováno v:
ASPET 2023 Annual Meeting Abstract - Cancer Pharmacology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51155eaf733ac5b384ab63e03bff2aba
https://doi.org/10.1124/jpet.122.208400
https://doi.org/10.1124/jpet.122.208400
Autor:
Sharyn D. Baker, Stanley Pounds, Jeffrey E. Rubnitz, Raul C. Ribeiro, Ching-Hon Pui, Sheila Shurtleff, James S. Blachly, Daelynn R. Buelow, Lie Li, John C. Panetta, Jolieke G. van Oosterwijk, Hiroto Inaba
Supplementary Figure from Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::159b56c1a32070e48daecdc31c97a8a3
https://doi.org/10.1158/1078-0432.22487999
https://doi.org/10.1158/1078-0432.22487999
Autor:
Sharyn D. Baker, Stanley Pounds, Jeffrey E. Rubnitz, Raul C. Ribeiro, Ching-Hon Pui, Sheila Shurtleff, James S. Blachly, Daelynn R. Buelow, Lie Li, John C. Panetta, Jolieke G. van Oosterwijk, Hiroto Inaba
Supplementary Data from Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28b61d101370e0fb0569650c7a41c9ce
https://doi.org/10.1158/1078-0432.22488014.v1
https://doi.org/10.1158/1078-0432.22488014.v1